Drug intelligence / Profile preview

Reforge

Development stage: Unknown
Lead developer: Atro Pharma
Administration: Oral

Overview

Reforge is an herbal nutraceutical oral tablet developed by Atro Pharma for the support of bone and joint health. It is part of a product portfolio focused on pain management and musculoskeletal wellness. Although the specific herbal ingredients and biological targets are not publicly detailed, the product is manufactured under Good Manufacturing Practices (GMP) standards and is intended to improve quality of life through joint support. It is administered orally and is currently available on the market as an approved health supplement.

Brand names: Reforge
Other names: Reforge Tablet

Beyond the preview

Go deeper on Reforge.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reforge.

Explore the full profile